Eris Lifesciences has strategically expanded its metabolic care range by officially launching its generic semaglutide medication branded as 'Sundae' in the Indian pharmaceutical market on 21 March 2026. The diabetes treatment medication represents a significant addition to the company's therapeutic portfolio, offering an affordable alternative for patients requiring semaglutide therapy and targeting nearly 70% of India's diabetes patient population.

Strategic Portfolio Expansion and Regulatory Filing

The company filed a press release under Regulation 30 of SEBI Listing Regulations on 20 March 2026, announcing the official launch date as 21 March 2026. This launch marks Eris Lifesciences' entry into the GLP-1 therapy segment, strengthening its metabolic care offerings. The product specifications and launch details include:

Competitive Pricing Strategy and Product Variants

Eris Lifesciences has positioned Sundae as a breakthrough in diabetes therapy accessibility with competitive pricing across multiple formats. The multi-dose vial variants are priced at ₹1,290 per month for both 2 mg/1.5 ml and 4 mg/3 ml strengths. The company plans to introduce pen-device versions in April with enhanced convenience:

Market Impact and Metabolic Care Focus

The launch represents Eris Lifesciences' strategic expansion into the GLP-1 therapy segment, leveraging its strong presence in diabetology across India while growing its metabolic care range. Semaglutide, a GLP-1 receptor agonist, provides transformative therapy for Type 2 diabetes and weight management through improved glycemic control and weight reduction. The company emphasized that this initiative democratizes access to innovative therapies while addressing India's growing diabetes burden and strengthening its position in the metabolic care market.

Manufacturing and Distribution Network

Sundae is manufactured by Vintus Pharmaceuticals at their Ahmedabad facility and is available across India through Eris Lifesciences' distribution network of approximately 5,000 stockists and 500,000+ retail pharmacies. The multi-dose vial format requires refrigerated storage and offers 42-day stability after first use, providing practical benefits for patients and healthcare providers while supporting the company's expanded metabolic care offerings.

Eris Lifesciences has completed the acquisition of branded probiotic products from Velbiom Probiotics Private Limited for ₹50 crores. The company's Board of Directors approved and executed the Business Transfer Agreement on March 20, 2026, marking the completion of this strategic acquisition in the probiotic segment.

Board Meeting Outcome

The Board of Directors meeting held on March 20, 2026, approved the execution of the Business Transfer Agreement and other connected documents with Velbiom Probiotics Private Limited. The meeting commenced at 12:45 P.M. and concluded at 03:15 P.M., with the BTA being duly executed the same day.

Acquisition Details

The acquisition involves the purchase of Velbiom's probiotic business as a going concern on a slump sale basis. Velbiom Probiotics is described as a science-driven bio-therapeutics company committed to India-specific microbiome-based therapy and research. The acquired portfolio consists of various formulations of prebiotics and probiotics for metabolic health, gut wellness, and women's health.

Financial Performance of Acquired Business

The acquired probiotic business has demonstrated consistent revenue performance over recent years. The financial data shows established market operations with steady revenue generation across different periods.

The revenue figures indicate a business with established market presence, having generated substantial revenues across the three-year period. This performance demonstrates the business's operational stability in the probiotic segment.

Strategic Significance

This acquisition enables Eris Lifesciences to enter the specialized probiotic products market through established branded offerings. The transaction provides immediate access to formulations targeting metabolic health, gut wellness, and women's health segments. The purchase represents a strategic expansion into the growing microbiome-based therapy market, leveraging Velbiom's science-driven approach and India-specific research focus.